Hippocrates Research: Published paper

1. Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, Siller-Matula J, Schnabel RB, Cemin R, Kirchhof P, De Caterina R.

Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy – A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries.

Int J Cardiol. 2018 Nov 1;270:160-166.

2. Colonna P, von Heymann C, Santamaria A, Matsushita Y, Unverdorben M. Edoxaban

Management in Diagnostic and Therapeutic Procedures (EMIT-AF/VTE)-Trial design.

Clin Cardiol. 2018:1-7.

3. Siller-Matula JM, Pecen L, Patti G, Lucerna M, Kirchhof P, Lesiak M, Huber K, Verheugt FWA, Lang IM, Renda G, Schnabel RB, Wachter R, Kotecha D, Sellal JM, Rohla M, Ricci F, De Caterina R; TEAM in AF group.

Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF – HF substudy.

Int J Cardiol. 2018 Aug 15;265:141-147

4. Cohen AT, Ay C, Hainaut P, Décousus H, Hoffmann U, Gaine S, Coppens M, da Silva PM, Castro DJ, Amann-Vesti B, Brüggenjürgen B, Levy P, Bastida JL, Vicaut E, Laeis P, Fronk EM, Zierhut W, Malzer T, Bramlage P, Agnelli G; ETNA-VTE-Europe investigators.

Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.

Thromb J. 2018 May 1;16:9.

5. Verze P, Arcaniolo D, Palmieri A, Cai T, La Rocca R, Franco M, Venturino L, De Sio M, Mirone V.

Premature Ejaculation Among Italian Men: Prevalence and Clinical Correlates From an Observational, Non-Interventional, Cross-Sectional, Epidemiological Study (IPER).

Sex Med. 2018 May 23.

6. Schnabel R, Pecen L, Engler D, Lucerna M, Sellal JM, Ojeda FM, De Caterina R, Kirchhof P.

Atrial fibrillation patterns are associated with arrhythmia progression and clinical outcomes.

Heart. 2018 Mar 17.

7. Figueira J, Fletcher E, Massin P, Silva R, Bandello F, Midena E, Varano M, Sivaprasad S, Eleftheriadis H, Menon G, Amaro M, Ayello Scheer S, Creuzot-Garcher C, Nascimento J, Alves D, Nunes S, Lobo C, Cunha-Vaz J; EVICR.net Study Group.

Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).

Ophthalmology. 2018 May;125(5):691-700.

8. De Caterina R, Brüggenjürgen B, Darius H, Köhler S, Lucerna M, Pecen L, Renda G, Schilling RJ, Schliephacke T, Zamorano JL, Le Heuzey JY, Kirchhof P.

Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.

Arch Cardiovasc Dis. 2018 Feb;111(2):74-84

9. Bauersachs R, Agnelli G, Gitt AK, Monreal M, Mismetti P, Willich SN, Laeis P, Fronk EM, Bramlage P, Cohen AT; PREFER in VTE Scientific Steering Committee.

The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry.

Thromb Res. 2017 Sep;157:181-188.

10. Patti G, Lucerna M, Pecen L, Siller-Matula JM, Cavallari I, Kirchhof P, De Caterina R.

Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation).

J Am Heart Assoc. 2017 Jul 23;6(7)

11. Cohen AT, Gitt AK, Bauersachs R, Fronk EM, Laeis P, Mismetti P, Monreal M, Willich SN, Bramlage P, Agnelli G, PREFER in VTE Scientific Steering Committee And The Prefer In Vte Investigators OBOT.

The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.

Thromb Haemost. 2017 Jun 27;117(7):1326-1337.

12. Antonini A, Barone P, Bonuccelli U et al.

ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson’s disease.

J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):317-324.

13. Renda G, Patti G, Sangiuolo R, Attena E, Malpezzi MG, De Caterina R; a nome dello Steering Committee del Registro Europeo PREFER in AF.

Management of thromboembolic risk in patients with atrial fibrillation in Italy: follow-up data from the PREFER in AF European Registry.

G Ital Cardiol (Rome). 2016 Nov;17(11):922-931

14. Epis OM, Casu C, Belloli L et al.

Pixel or Paper? Validation of a Mobile Technology for Collecting Patient-Reported Outcomes in Rheumatoid Arthritis.

JMIR Res Protoc. 2016 Nov 16;5(4):e219.

15. Frisinghelli A, Cesana F, Clavario P et al.

Italian cardiologists and tobacco smoking. A survey on the prevalence and knowledge of smoking and strategies for smoking cessation in a cohort of Italian cardiologists.

G Ital Cardiol 2015;16: 426-432.

16. Monteleone G, Neurath MF, Ardizzone S et al.

Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease.

N Engl J Med. 2015 Mar 19;372(12):1104-13.

17. De Caterina R, Ammentorp B, Darius H, Le Heuzey JY, Renda G, Schilling RJ, Schliephacke T, Reimitz PE, Schmitt J, Schober C, Zamorano JL, Kirchhof P; PREFER in AF Registry Investigators.

Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe.

Heart. 2014 Oct;100(20):1625-35. doi: 10.1136/heartjnl-2014-305486.

18. De Caterina R, Renda G, Sangiuolo R, Attena E, Di Lecce L, Romeo F; Steering Committee del Registro Europeo PREFER in AF.

Management of thromboembolic risk in patients with atrial fibrillation in Italy: baseline data from the PREFER in AF European Registry.

G Ital Cardiol (Rome). 2014 Feb;15(2):99-109.

19. Certan D, Righini V, Oliva M et al.

Bioavailability of l-thyroxine and its metabolites after topical treatment with an emulsion containing 0.1% micronised l-thyroxine.

G Ital Dermatol Venereol. 2013 Jun;148(3):287-92.

20. Zorzi F, Calabrese E, Monteleone I, et al.

A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn’s disease.

Aliment Pharmacol Ther. 2012 Nov;36(9):850-7.

21. Monteleone G, Fantini MC, Onali S et al.

Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn’s disease.

Mol Ther. 2012 Apr;20(4):870-61.

22. Zaim M, Piselli L, Fioravanti P et al.

Efficacy and tolerability of a prolonged release ferrous sulphate formulation in iron deficiency anaemia: a non-inferiority controlled trial.

Eur J Nutr. 2012 Mar;51(2):221-9.

23. Neuzillet Y, Naber KG, Schito G, Gualco L, Botto H.

French results of the ARESC study: clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy.

Med Mal Infect. 2012 Feb;42(2):66-75.

24. Chlabicz S, Leszczynska K, Lukas W, Gualco L, Schito G, Naber KG.

Uncomplicated lower urinary tract infections in females–clinical aspects, aetiology and antimicrobial resistance epidemiology. Results of the ARESC (Antimicrobial Resistance Epidemiological Survey on Cystitis) study in Poland and their implications for empiric therapy.

Przegl Epidemiol. 2011;65(2):345-51.

25. Perepanova TS, Siniakova LA, Zaĭtsev AV, Kozlov RS, Shevelev AN, Gualco L, Achito G, Naber KG.

Russian results of the international epidemiological study of clinical aspects and resistance to antimicrobial medicines of cystitis uropathogens in females (ARESC): significance of empiric therapy.

Urologiia. 2011 Mar-Apr;(2):30-6.

26. Schito GC, Gualco L, Naber KG, Botto H, Palou J, Mazzei T, Marchese A.

Do different susceptibility breakpoints affect the selection of antimicrobials for treatment of uncomplicated cystitis?

J Chemother. 2010 Oct;22(5):345-54.

27. Rolando M, Bonini S, Aragona- P, Modorati GM, Barabino S. Lacrima.

The Italian Register of Patients with Tear Dysfunction.

TFOS (Tear Film and Ocular Surface), Florence 23-25 sept 2010. (poster).

28. Wagenlehner FM, Wagenlehner C, Savov O, Gualco L, Schito G, Naber KG.

Clinical aspects and epidemiology of uncomplicated cystitis in women. German results of the ARESC Study.

Urologe A. 2010 Feb;49(2):253-61.

29. Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A.

The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections.

Int J Antimicrob Agents. 2009 Nov;34(5):407-13.

30. Naber KG, Schito G, Botto et al.

Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy.

Eur Urol. 2008 Nov;54(5):1164-75.

bodoni bodoniPublished Paper